Are the Polyomaviruses BK and JC Associated with Opportunistic Infections, Graft-versus-Host Disease, or Worse Outcomes in Adult Patients Receiving Their First Allogeneic Stem Cell Transplantation with Low-Dose Alemtuzumab? by Schneidewind, Laila et al.
E-Mail karger@karger.com
 Original Paper 
 Acta Haematol 2017;138:3–9 
 DOI: 10.1159/000468972 
 Are the Polyomaviruses BK and JC Associated 
with Opportunistic Infections, Graft-versus-Host 
Disease, or Worse Outcomes in Adult Patients 
Receiving Their First Allogeneic Stem Cell 
Transplantation with Low-Dose Alemtuzumab? 
 Laila Schneidewind a    Thomas Neumann b    Florian Knoll b    Kathrin Zimmermann c    
Sigrun Smola a    Christian Andreas Schmidt b    William Krüger b  
 a  Institute of Virology, Saarland University Medical Center, Saarland University,  Homburg/Saar , and  b  Department of 
Haematology/Oncology, and  c  Friedrich Loeffler Institute of Medical Microbiology, University Medicine Greifswald, 
 Greifswald , Germany 
or JCPyV with CMV reactivation, Epstein-Barr virus reactiva-
tion, human herpes virus 6, or parvovirus B19 infection re-
quiring treatment. There was a significant correlation of
BKPyV-associated hemorrhagic cystitis with toxoplasmosis 
( p = 0.013). Additionally, there was a significant link of simul-
taneous BKPyV and JCPyV viruria with toxoplasmosis ( p = 
0.047). BKPyV and JCPyV were not associated with GvHD, re-
lapse, or death.  Conclusion: We found no association of 
 BKPyV or JCPyV with viral infections or GvHD. Only the cor-
relation of both polyomaviruses with toxoplasmosis was sig-
nificant. This is a novel and interesting finding. 
 © 2017 S. Karger AG, Basel 
 Introduction 
 The polyomaviruses BK (BKPyV) and JC (JCPyV) may 
cause opportunistic infections in immunocompromised 
patients  [1] . BK viruria occurs in up to 100% of stem cell-
transplanted patients and can lead to BKPyV-associated 
hemorrhagic cystitis in up to 40%  [2] . Less frequent in 
these patients are JC viruria and JCPyV-associated hem-
orrhagic cystitis, but JCPyV is still an important pathogen 
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 Abstract 
 Background: The association of polyomaviruses BK and JC 
with other opportunistic infections and graft-versus-host 
disease (GvHD) in allogeneic stem cell transplantation is con-
troversially discussed.  Methods: We conducted a retrospec-
tive study of 64 adult patients who received their first alloge-
neic stem cell transplantation between March 2010 and De-
cember 2014; the follow-up time was 2 years.  Results: Acute 
leukemia was the most frequent underlying disease (45.3%), 
and conditioning included myeloablative (67.2%) and non-
myeloablative protocols (32.8%). All patients received 10 mg 
of alemtuzumab on day –2 (20 mg in case of mismatch) as 
GvHD prophylaxis. Twenty-seven patients (41.5%) devel-
oped cytomegalovirus (CMV) reactivation. BKPyV-associated 
hemorrhagic cystitis was diagnosed in 10 patients (15.6%). 
Other opportunistic infections caused by viruses or protozoa 
occurred rarely (<10%). There was no association of BKPyV 
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since it can cause progressive multifocal leukoencepha-
lopathy  [3, 4] . The most important point about these viral 
infections is that they can lead to severe morbidity in stem 
cell-transplanted patients. For example, in a retrospective 
study of allogeneic stem cell transplantation with 2,477 
patients, BK viruria was significantly associated with a loss 
of kidney function and a worse overall survival  [5] . Near-
ly the same results were described before by Gilis et al.  [6] 
and the authors also placed emphasis on the high financial 
costs of treating this complication.
 Different risk factors and other opportunistic infec-
tions associated with these viruses have been discussed 
controversial lately, but there is a lack of data for adult 
allogeneic stem cell transplantation. Several studies arise 
from kidney or solid organ and pediatric stem cell trans-
plantation. Another problem are the heterogenic popula-
tions of these studies, as they include different condition-
ing regimes such as antithymoglobulin or alemtuzumab. 
Especially for alemtuzumab, dosing is also a major issue 
in terms of adverse events, including opportunistic infec-
tions or infectious complications  [7] . To our knowledge 
there are no studies on low-dose alemtuzumab for graft-
versus-host disease (GvHD) prophylaxis in adult alloge-
neic stem cell transplantation and its association with the 
BKPyV or JCPyV. However, there are also sparse da-
ta for JCPyV in comparison to BKPyV. The correlation 
with other opportunistic infections like cytomegalovirus 
(CMV), human herpes virus 6 (HHV-6), or Epstein-Barr 
virus (EBV) and the association with GvHD are contro-
versially discussed  [8–11] . Since BKPyV and JCPyV are 
important pathogens in allogeneic stem cell transplanta-
tion, it is important to know the risk factors and associ-
ated infections. This knowledge is important to develop 
further prospective clinical trials and experimental stud-
ies for drug development, as no causal therapy has been 
established so far.
 Therefore, we conducted a retrospective analysis of 
adult patients receiving their first allogeneic stem cell 
transplantation in a single institution (University Medi-
cine Greifswald) uniformly using low-dose alemtuzumab 
as GvHD prophylaxis. The analyzed endpoints were the 
correlation of BKPyV and JCPyV with other transplant-
associated opportunistic infections and acute or chronic 
GvHD.
 Materials and Methods 
 Development of This Study and Study Population 
 This study was designed according to the guidelines in the syn-
thesis of qualitative research (ENTREQ) (equatornetwork.org), an 
international initiative that provides robust reporting guidelines 
 [12] .
 Data from patients’ records, including demographic charac-
teristics, patient history, and the results of blood and urine tests 
and other related tests in adult patients with hematological disease 
who underwent their first allogeneic stem cell transplantation 
from March 2011 to December 2014 at our institution were col-
lected. The observation period was from the beginning of the con-
ditioning therapy until 2 years after stem cell transplantation; out-
patient data were included. We decided to start this study at that 
time since a quantitative PCR for BKPyV and JCPyV had been 
established in the Institute of Medical Microbiology at the Uni-
versity of Greifswald by then. For that time period we could iden-
tify 68 eligible patients, but we finally excluded 4 patients due to 
incomplete data.
 Afterwards, a data bank of these patients was established using 
SPSS 23.0 software.
 All of the procedures performed in this study were in accor-
dance with the ethical standards of the institutional and/or na-
tional research committee and in compliance with the 1964 Hel-
sinki Declaration and its later amendments or comparable ethical 
standards. For this type of study, formal consent was not required.
 Assessment of Infectious Complications 
 BKPyV and JCPyV were assessed by quantitative PCR in urine 
using a commercially available kit (LightMix Polyoma JC-BK; Tib 
Molbiol, Germany) on clinical suspicion only (mainly hemorrhag-
ic cystitis); no other material (i.e., blood samples) was analyzed
for BKPyV and JCPyV. BKPyV-associated cystitis was defined
as hemorrhagic cystitis with macrohematuria in the presence of 
BKPyV in urine.
 CMV reactivation and urinary tract infections were assessed on 
a regular basis during in-house treatment. CMV was assessed in 
blood samples at least 2 times a week by quantitative PCR; UTI was 
assessed at least 1 time a week by midstream urine sampling and 
culture, both regardless of clinical signs or symptoms during the 
inpatient treatment. During outpatient treatment and follow-up, 
CMV-DNA was measured quantitatively by rt-PCR up to day 
+100 on every visit.
 The other infectious pathogens like EBV, HHV-6, toxoplasmo-
sis, and parvovirus B19 were assessed by PCR on clinical suspicion 
only (e.g., in case of fever, diarrhea, rash, or any other symptom 
compatible with an infection).
 Preemptive antiviral treatment of CMV reactivation with gan-
ciclovir or foscarnet was started in cases of 1,000 copies/mL. Treat-
ment of all other infections or reactivations was initiated at the 
decision of the physician in charge.
 Definitions and Statistical Analysis 
 Day 0 of the timeline was defined as the day of infusion of the 
stem cell product. Engraftment of leukocytes was the first of 3 con-
secutive days with a leukocyte count of at least 1 × 109/L. In the 
same way, engraftment of thrombocytes was defined as the first of 
3 consecutive days with a platelet count of at least 20 × 10 9 /L, fol-
lowed by a transfusion-independent increase above 20 × 10 9 /L.
 Only infections requiring treatment were included in our anal-
ysis. In our study, we defined CMV reactivation, EBV reactivation, 
HHV-6 and parvovirus B19 infection, or toxoplasmosis as an in-
fection and/or reactivation requiring treatment (e.g., rituximab 
therapy in case of EBV reactivation).
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 For each numeric variable, the numeric distribution was pre-
liminarily assessed via the Kolmogorov-Smirnov test; due to the 
small sample size, histograms were also used. Descriptive statistics 
were obtained (i.e., means ± SD for normal distributions or with 
medians [range] for nonparametric data). The χ 2 test (parametric) 
and the Mann-Whitney U test (nonparametric) were used for cat-
egorical and continuous variables, respectively. Survival data were 
assessed using the Kaplan-Meier method. All reported  p values 
were based on a 2-sided hypothesis.  p < 0.05 was considered statis-
tically significant.
 All statistical calculations were performed using Statistical 
Package for the Social Sciences 23.0 software (SPSS Inc., Chicago, 
IL, USA).
 Results 
 Demographic Characteristics of the Study Population 
 The baseline characteristics are shown in  Table 1 . We 
found a population as expected for adult allogeneic stem 
cell transplantation, with a median age of 52.0 years and 
acute myeloid leukemia as the most frequent disease ( n = 
22; 34.4%). All patients received low-dose alemtuzumab 
(10 mg on day –2; respectively, 20 mg in case of mis-
match) for GvHD prophylaxis. Conditioning included 
myeloablative (67.2%) and nonmyeloablative protocols 
(32.8%).
 Transplantation Data 
 Table 2 shows all of the relevant transplantation data 
including the inpatient treatment.
 BK and JC Virus Infections during the Inpatient 
Treatment Period 
 During the inpatient treatment period BK viruria oc-
curred in 22 patients (34.4%), and 10 of those patients 
with viruria developed BKPyV-associated hemorrhagic 
cystitis (15.6%).
 Only 9 patients (14.1%) developed JC viruria, and 6 of 
those patients (9.4%) had symptomatic JC viruria, mean-
ing urogenital symptoms like dysuria, alguria, or macro-
hematuria at the time of JC viruria. Interestingly, JC viru-
ria is significantly associated with urogenital symptoms 
( p < 0.001). Therefore, we defined these cases as JC virus-
associated cystitis. Four patients (6.2%) developed simul-
taneous BK and JC viruria.
 Bacterial Urinary Tract Infections during the 
Inpatient Treatment 
 Ten patients (15.6%) had a bacterial urinary tract in-
fection defined as significant bacteriuria in midstream 
urine in the presence of urogenital symptoms.  Escherich-
 Table 1.  Demographic characteristics of the study population
(n = 64)
Gender
Male 38 (59.4)
Female 26 (40.6)
Hematological disease
AML 22 (34.4)
NHL 18 (28.2)
ALL 8 (12.5)
MDS 7 (10.9)
CLL 2 (3.1)
CML 2 (3.1)
MPS 2 (3.1)
Acute biphenotypic leukemia 2 (3.1)
T-prolymphocytic leukemia 1 (1.6)
Age, years 52.0 (20 – 72)
Conditioning regime
Bu/Cy 42 (65.6)
Flu/TBI 8 (12.5)
Treo/Flu 6 (9.4)
Bu/Flu 4 (6.3)
Flu/Cy 2 (3.1)
Flu/Mel 1 (1.6)
Cy/TBI 1 (1.6)
 Values are presented as numbers (%) or medians (range). AML, 
acute myeloid leukemia; NHL, non-Hodgkin lymphoma; ALL, 
acute lymphatic leukemia; MDS, myelodysplastic syndrome; CLL, 
chronic lymphatic leukemia; CML, chronic myeloid leukemia; 
MPS, myeloproliferative syndrome; Bu, busulfan; Cy, cyclophos-
phamide; Flu, fludarabine; TBI, total bone irradiation; Treo, treo-
sulfane; Mel, melphalan.
 Table 2.  Transplantation data of the study population (n = 64)
Donor
Matched related donor 16 (25.0)
Matched unrelated donor 27 (42.2)
Mismatched unrelated donor 21 (32.8)
Duration of leukopenia, days 14.0 (10 – 31)
Duration of thrombocytopenia, days 10.0 (0 – 48)
Transfused packed red blood cells, n 7.1 ± 5.9
Transfused packed platelets, n 3.9 ± 4.5
Transfused fresh frozen plasma, n 0.5 ± 2.6
Primary immunosuppression (day 1)
Cyclosporine A 44 (68.8)
Cyclosporine A + mycophenolate mofetile 20 (31.2)
Neutropenic fever during inpatient treatment
No 22 (34.4)
Yes 42 (65.4)
Duration of inpatient treatment, days 45.0 (23 – 114)
Values are presented as numbers (%), means ± SD, or medians 
(range).
 Schneidewind/Neumann/Knoll/
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ia coli  was the most frequent bacteria (80%), followed by 
 Enterococci  (20%).
 We observed no association between bacterial urinary 
tract infection and BK viruria ( p = 0.751) or BKPyV-as-
sociated hemorrhagic cystitis ( p = 0.678). The same ob-
servation was made for JC viruria ( p = 0.678) and JCPyV-
associated cystitis ( p = 0.941). When BK and JC viruria 
developed at the same time point, they were also not 
linked to bacterial urinary tract infection ( p = 0.374).
 Association of BK and JC Virus with the Occurrence of 
Neutropenic Fever during Inpatient Treatment 
 Neutropenic fever during inpatient treatment was not 
associated with BK viruria ( p = 0.755) or BKPyV-associ-
ated hemorrhagic cystitis ( p = 0.683), nor was JC viruria 
( p = 0.408) and JCPyV-associated cystitis ( p = 0.955) or 
the presence of BK and JC virus in urine at the same time 
( p = 0.683).
 Association of Opportunistic Infections Needing 
Treatment and BK and JC Virus 
 We analyzed the data for EBV, CMV, HHV-6, toxo-
plasmosis, and parvovirus B19 infection needing treat-
ment until 2 years after transplantation. In this study pop-
ulation EBV occurred 2 times (3.1%), CMV reactivation 
27 times (41.5%), HHV-6 infection also 2 times (3.1%), 
toxoplasmosis 3 times (4.6%), and parvovirus B19 infec-
tion 4 times (6.2%). Two of the 3 patients with toxoplas-
mosis also developed BK cystitis. The level of significance 
for each constellation is shown in  Table 3 . Interestingly, 
we only observed a significant correlation of BK cystitis 
or simultaneous BK and JC viruria with toxoplasmosis.
 Association of BK and JC Virus with GvHD 
 Acute GvHD occurred in 23 patients (35.9%), with 
skin as the most frequent manifestation location ( n = 16; 
25%), followed by the bowel ( n = 7; 10.9%) and the liver 
( n = 1; 1.6%). Slight complications (grade I and II GvHD) 
appeared 13 times (20.3%) and severe adverse events 
(grade III and IV GvHD) 11 times (17.2%). Chronic 
GvHD was observed in 5 patients (7.8%), with a planned 
follow-up of 2 years after infusion of the stem cell prod-
uct. Three patients had a skin manifestation (4.7%) with 
limited disease and 2 patients a chronic GvHD of the 
bowel with extensive disease (3.1%). The association of 
BKPyV and JCPyV with acute and chronic GvHD is 
shown in  Table 4 .
 Table 3.  Association between opportunistic infections needing treatment and BK and JC virus in the study pop-
ulation (n = 64)
Opportunistic infection BK viruria BK cystitis JC viruria JC cystitis Simultaneous BK 
and JC viruria
Epstein-Barr virus 0.636 0.536 0.561 0.644 0.711
Cytomegalovirus 0.886 0.586 0.381 0.202 0.744
Human herpes virus 6 0.636 0.536 0.561 0.644 0.711
Toxoplasmosis 0.228 0.013 0.325 0.145 0.047
Parvovirus B19 0.077 0.374 0.403 0.506 0.594
Numbers are p values. Bold values indicate statistical significance (p < 0.05).
 Table 4.  Association of acute and chronic GvHD with BK and JC virus in the study population (n = 64)
BK viruria BK cystitis JC viruria JC cystitis Simultaneous BK 
and JC viruria
Acute GvHD 0.619 0.771 0.186 0.099 0.638
Chronic GvHD 0.783 0.316 0.691 0.454 0.548
Numbers are p values. GvHD, graft-versus-host disease.
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 Association of BK and JC Virus with Outcome Data 
and Survival 
 Since we analyzed the opportunistic infections and 
GvHD until 2 years after stem cell transplantation, we 
also show the survival data. The median survival time was 
18.5 months, with a range of 1–65 months. At the time of 
reporting, 33 patients had died (50.8%) and 19 patients 
had had a relapse (29.2%). No association between the 
polyomaviruses BK and JC with relapse or death was 
found, and this is shown in  Table 5 . The Kaplan-Meier 
curve is shown in  Figure 1 .
 Discussion 
 We conducted a retrospective study in a population of 
adult patients receiving their first allogeneic stem cell 
transplantation with low-dose alemtuzumab as GvHD 
prophylaxis, starting after established quantitative PCR 
for the polyomaviruses BK and JC. To our knowledge, 
this is the first study with a low-dose alemtuzumab stem 
cell transplantation population focused on BKPyV and 
JCPyV and their association with opportunistic infec-
tions and GvHD.
 We must assume that this study still has a small sample 
size, but it is homogenous in terms of GvHD prophylaxis.
 BKPyV- and JCPy-associated hemorrhagic cystitis 
were relatively rare in our population. For example, BK 
cystitis only occurred in 15.6% of cases despite literature 
references which describe this kind of cystitis in up to 
40% of patients  [2] . Infectious complications like CMV 
reactivation or toxoplasmosis are expected problems in 
these immunocompromised patients, but we found 
sparse adverse events in terms of these analyzed infec-
tions. Interestingly, although the question of whether 
BKPyV is associated with other typical transplantation-
re lated infections like CMV reactivation is controversial-
ly discussed, JCPyV has been less investigated. In their ret-
rospective analysis of 339 patients who underwent alloge-
neic stem cell transplantation, Uhm et al.  [13] described 
CMV viremia as a significant risk factor for BKPyV-asso-
ciated hemorrhagic cystitis, but another study with kid-
ney-transplanted patients under immunosuppression 
identified CMV as a protecting factor against BKPyV in-
fection  [13, 14] . We found no significant association of 
BKPyV and JCPyV with CMV in our patients. One rea-
son for the controversial results described in several dif-
ferent studies might be the different patterns of immuno-
suppressive therapy also including alemtuzumab or anti-
thymoglobulin; another problem is that most of those 
studies are retrospective. In our opinion, further prospec-
tive studies with exact drug monitoring and monitoring 
of the immune system, like T-cell counts, are necessary to 
 Table 5.  Association of BK and JC virus with relapse or death in the study population (n = 64)
BK viruria BK cystitis JC viruria JC cystitis Simultaneous BK 
and JC viruria
Relapse 0.381 0.981 0.798 0.839 0.833
Death 0.857 0.564 0.647 0.936 0.949
Numbers are p values. 
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 Fig. 1. Kaplan-Meier survival curve of the study population ( n = 
64). 
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answer those questions. Furthermore, dosing of drugs 
like alemtuzumab is important. As we already mentioned, 
a big advantage of our analysis is the unified GvHD pro-
phylaxis with low-dose alemtuzumab in the whole study 
population since a higher dose might trigger more infec-
tious complications, as has been described before  [7] . 
However, authors of studies with bigger samples sizes 
could argue that the data could not reach significance be-
cause of our small sample size, but with  p values ranging 
from 0.8 to 0.2 it is mathematically unlikely that statistical 
significance will be reached with a sample size of 300. The 
same consideration could be made regarding the other 
analyzed subjects, especially GvHD, which will be dis-
cussed later.
 Data for other transplant-associated infections are 
rare. Quintela et al.  [8] reported that HHV-6 infection in 
allogeneic stem cell transplanted patients is significantly 
associated with CMV and BKPyV infections. To our 
knowledge, no data on JCPyV and other transplant-asso-
ciated infections are currently available. Certainly, we 
cannot compare our study with the data of Quintela et al. 
 [8] since the authors analyzed a very heterogenic popula-
tion of stem cell-transplanted patients and the analysis 
was focused on chromosomal integration, viral coinfec-
tions, and T-cell reconstitution patterns.
 Interestingly, we only found a significant correlation 
of BKPyV-associated hemorrhagic cystitis and simulta-
neous BK and JC viruria with toxoplasmosis requiring 
treatment. This is a novel finding. One explanation might 
be the high level of immunosuppression at the time when 
toxoplasmosis, BK, and JC viruria occurred but, to an-
swer this question precisely, prospective data with drug 
and immune system monitoring are needed. Further-
more, it might only be a coincidence or maybe the poly-
omaviruses BK and JC require the same immune re-
sponses like toxoplasmosis, but there is a lack of data re-
garding this issue as well.
 The data regarding BKPyV and the association with 
GvHD are controversial, but most analyses have found 
that BKPyV is associated with acute GvHD  [11, 15] . In-
terestingly, Peterson et al.  [11] also performed a retro-
spective analysis in a homogenous population of adult 
allogeneic stem cell-transplanted patients receiving an 
FLAMSA-RIC protocol for conditioning and antithymo-
globuline for GvHD prophylaxis and they found a sig-
nificant association of BK viruria with acute GvHD. In 
comparison, our patients with no association with acute 
and chronic GvHD received low-dose alemtuzumab, but 
both studies are retrospective. As we mentioned before, a 
prospective evaluation with drug monitoring is neces-
sary. Just as we stated for infections, reports about JCPyV 
and GvHD in the literature are rare, but in our population 
there was no correlation of JCPyV with GvHD.
 One surprising result about JCPyV is that the virus is 
often associated with urological symptoms like dysuria 
even when there is only viruria without hematuria. This 
might not be important for patients’ morbidity or mortal-
ity because there was also no link of the virus with relapse 
or death, but it may be relevant for patients’ sense of com-
fort. Thus, we might have to consider a symptomatic 
therapy when the patient complains about symptoms like 
dysuria.
 We found no association of BKPyV with relapse or 
death (meaning mortality), but BKPyV still might be im-
portant for patients’ morbidity or worse outcomes, as we 
and others have reported before  [6, 16] .
 Of course (as in every retrospective study with a small 
sample size) we have to assume that our data is biased, 
especially as data on BKPyV and JCPyV viruria were col-
lected on patients with a clinical suspicion only.
 Despite the mentioned limitations of our analysis, it 
also has advantages, like the homogenous study popula-
tion in terms of GvHD prophylaxis with low-dose alem-
tuzumab, and the fact that it presents the first data on the 
association of BKPyV and JCPyV with toxoplasmosis and 
data on the absent association of both polyomaviruses 
with GvHD and EBV, CMV, HHV-6, and parvovirus 
B19.
 On the whole, in our study of adult allogeneic stem cell 
transplant recipients receiving low-dose alemtuzumab 
for GvHD prophylaxis we found a low frequency of viral 
reactivations and no association of BKPyV or JCPyV with 
severe viral infections or GvHD. BKPyV-associated hem-
orrhagic cystitis is significantly correlated with toxoplas-
mosis in this population. Further prospective studies with 
drug and immune system monitoring are necessary to 
elucidate the link of polyomavirus BK and JC to other 
transplant-associated infections like CMV reactivation. 
Even the development of a clinical model system might 
be helpful to improve patient care.
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